Short Interest in MetaVia Inc. (NASDAQ:MTVA) Decreases By 53.4%
by Danessa Lincoln · The Markets DailyMetaVia Inc. (NASDAQ:MTVA – Get Free Report) saw a large decrease in short interest in July. As of July 31st, there was short interest totaling 160,464 shares, a decrease of 53.4% from the July 15th total of 344,566 shares. Approximately 3.1% of the company’s stock are short sold. Based on an average daily volume of 100,346 shares, the days-to-cover ratio is currently 1.6 days.
MetaVia Price Performance
Shares of NASDAQ:MTVA traded up $0.03 during midday trading on Friday, hitting $1.49. 69,155 shares of the company’s stock were exchanged, compared to its average volume of 91,237. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03. The company has a market cap of $7.69 million, a PE ratio of -0.46 and a beta of 0.95. The stock has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.69.
MetaVia (NASDAQ:MTVA – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). On average, analysts anticipate that MetaVia will post -2.79 EPS for the current fiscal year.
Institutional Investors Weigh In On MetaVia
A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
MTVA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating on shares of MetaVia in a report on Friday, July 10th. Finally, Wall Street Zen raised MetaVia to a “sell” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.00.
View Our Latest Research Report on MTVA
About MetaVia
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.